ArticleDigestive diseases and sciences2010
EpCAM: a potential antimetastatic target for gastric cancer.
Article in Digestive diseases and sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Pooled it
- Clinicopathologic Characteristics of Trop Family Proteins (Trop-2 and EpCAM) in Gastric Carcinoma.Journal of gastric cancer · 2024Article
- An Intrabody against B-Cell Receptor-Associated Protein 31 (BAP31) Suppresses the Glycosylation of the Epithelial Cell-Adhesion Molecule (EpCAM) via Affecting the Formation of the Sec61-Translocon-Associated Protein (TRAP) Complex.International journal of molecular sciences · 2023Article
- Significant co-expression of putative cancer stem cell markers, EpCAM and CD166, correlates with tumor stage and invasive behavior in colorectal cancer.World journal of surgical oncology · 2022Article
- Anti-EpCAM antibodies for detection of metastatic carcinoma in effusions and peritoneal wash.Oncology letters · 2019Article
- Synthesis of saporin-antibody conjugates for targeting EpCAM positive tumour cells.IET nanobiotechnology · 2019Article
- Clinicopathology of EpCAM and EGFR in Human Epithelial Ovarian Carcinoma.Open medicine (Warsaw, Poland) · 2017Article
- Increased expression of chymase in inflammatory polyps in elderly patients with functional bowel disorder.Experimental and therapeutic medicine · 2014Article
- High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric cancer.Targeted oncology · 2013Article
- High EpCAM expression is linked to proliferation and lauren classification in gastric cancer.BMC research notes · 2013Article
- Expression of GA733-Fc fusion protein as a vaccine candidate for colorectal cancer in transgenic plants.Journal of biomedicine & biotechnology · 2012Article
- Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research.Cellular and molecular life sciences : CMLS · 2011Article
- Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer.British journal of cancer · 2011Article
- Identification of novel molecular markers for detection of gastric cancer cells in the peripheral blood circulation using genome-wide microarray analysis.Experimental and therapeutic medicine · 2011Article
- Targeted DNA methylation by a DNA methyltransferase coupled to a triple helix forming oligonucleotide to down-regulate the epithelial cell adhesion molecule.Bioconjugate chemistry · 2010Article
Corrections and comments
- Retraction · 2013-05-28Duplication of Text · Euphemisms for Duplication ·
- Retracted
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEpithelial cellular adhesion molecule (EpCAM) is an attractive immunotherapeutic target to overcome metastasis of a variety of epithelium-oriented cancers. Edrecolomab, one kind of EpCAM monoclonal antibody (Panorex), has been approved for clinical application as postoperative adjuvant therapy in breast and colorectal cancer. However, the role of EpCAM in gastric cancer metastasis remains unclear.
resultsEpCAM was found to be more highly overexpressed in metastatic gastric cancer than in nonmetastatic samples by immunohistochemistry staining. The expression level of EpCAM in gastric cancer cell lines was determined by reverse-transcription polymerase chain reaction (RT-PCR) and Western blotting, respectively. Downregulation of EpCAM by small interfering RNA (siRNA) significantly suppressed in vitro adhesive, invasive, and migratory and in vivo metastatic abilities of gastric cancer cells.
conclusionWe provide first evidence that EpCAM contributes to the migration of gastric cancer, suggesting that EpCAM-targeted therapy might be a promising strategy in metastatic gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.